Publications by authors named "A Rutten"
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC).
Patients And Methods: Part 1 determined the recommended dose for expansion of T-DXd plus nivolumab. Part 2 evaluated efficacy and safety; the primary endpoint was confirmed objective response rate by independent central review.
Associations between gut microbiota and sarcopenia or its defining parameters in older adults: A systematic review.
J Cachexia Sarcopenia Muscle
December 2024
Altered gut microbiota (GM) potentially contribute to development or worsening of sarcopenia through a gut-muscle axis. This systematic review aims to compare GM between persons with sarcopenia or low sarcopenia-defining parameters (muscle mass, strength, and physical performance) to those with preserved muscle status, as well as to clarify possible associations between sarcopenia (-defining parameters) and relative abundance (RA) of GM-taxa or GM-(α- or β) diversity indices, in order to clarify whether there is robust evidence of the existence of a GM signature for sarcopenia. This systematic review was conducted according to the PRISMA-reporting guideline and pre-registered on PROSPERO (CRD42021259597).
View Article and Find Full Text PDFBackground: LHC165 is a Toll-like receptor (TLR)-7 agonist that generates an effective tumor antigen-specific T-cell adaptive immune response as well as durable antitumor responses. We aimed to evaluate the safety, tolerability, efficacy, dose-limiting toxicities, and pharmacokinetics (PK) of LHC165 single agent (SA) ± spartalizumab [PDR001; anti-programmed cell death protein 1 (PD-1)] in adult patients with advanced solid tumors.
Materials And Methods: In this phase I/Ib, open-label, dose-escalation/expansion study, patients received LHC165 SA 100-600 μg biweekly through intratumoral (IT) injection and LHC165 600 μg biweekly + spartalizumab 400 mg Q4W through intravenous (IV) infusion.
Article Synopsis
- Malignant sweat gland tumors, particularly eccrine porocarcinoma (EP), are rare, with about 18% of benign eccrine poroma (EPO) cases progressing to EP, highlighting a need for more understanding of EP biology and mutations involved in this transformation.
- Transcriptome profiling of 23 EP and normal skin samples showed significant gene expression diversity and downregulation in EP, including specific genes that indicated a stepwise transition from normal skin to EPO to EP.
- The study suggests that EP has a complex molecular nature linked to tumor development, with potential involvement of the p53 and EGFR pathways, and calls for further research with larger sample sizes to validate these findings.
Aims: The majority of dermatofibrosarcoma protuberans (DFSP) harbour PDGFB or PDGFD rearrangements. We encountered ALK expression/rearrangement in a PDGFB/D-negative CD34-positive spindle cell neoplasm with features similar to DFSP, prompting evaluation of ALK-rearrangements in DFSP and plaque-like CD34-positive dermal fibroma (P-LDF).
Methods And Results: We searched the archives of academic institutions for cases previously coded as DFSP and P-LDF.